人工智能促进药物研发

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology Pub Date : 2024-08-09 DOI:10.1038/s41585-024-00931-6

Louise Lloyd

引用次数: 0

摘要

利用 Rosetta 软件和在线服务器进行虚拟筛选，设计了一种针对前列腺癌治疗 p300 的蛋白水解靶向嵌合体药物。Rosetta 计算了总体界面结合得分和折叠稳定性得分。选择每个界面位点频率最高的氨基酸生成最终的多肽序列，即 CPWIWDGDNKDDNSTDGGGSGGTSFEQFWAWLWP。这种新药在耐阉割、AR 和神经内分泌前列腺癌细胞中显示出有效的 p300 降解和癌细胞杀伤能力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

AI for drug discovery

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Urology 医学-泌尿学与肾脏学

CiteScore

12.50

自引率

2.60%

发文量

123

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.